The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
NCT01056419 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2010-01-26
Summary
The relationship between the method of the treatment of hyperthyroidism due to Graves' disease and the course of Graves' ophthalmopathy is debated. The investigators aimed to compare the results of total thyroidectomy done in 6 months following the appearance of the symptoms of ophthalmopathy and the antithyroid drug therapy in patients with moderate to severe Graves' ophthalmopathy.
The inclusion criteria: 1)Hyperthyroidism and moderate to severe Graves' ophthalmopathy within 6 months, 2)Thyroid volumes greater than or equal to 15 mL in thyroid ultrasonography, 3)Patients taking no treatment except local medications for Graves' ophthalmopathy, 4)Clinical activity score of 3/7 or more, proptosis greater than or equal to 21 mm in one eye or 2 mm difference between two eyes, presence of diplopia, the opening of the eye lid greater than or equal to 9 mm.
All patients will be treated with antithyroid drug until TSH levels of the patients are between 0.4-1. During this period all the patients will take pulse methyl prednisolone treatment of a total dose of 4.5 gr. After pulse steroid treatment the patients will be randomised to two groups: one group will be sent to surgery for total thyroidectomy, and their TSH levels will be kept between 0.4-1 with levothyroxine treatment; the other group will be followed under antithyroid drug treatment and their TSH levels will be kept between 0.4-1 also.
The smoking habits will be asked. Serum TSH, fT4 levels, Hertelmeter and eye lid opening measurements, clinical activity scores, diplopia will be evaluated monthly; TSH receptor antibody, anti-thyroid peroxidase and anti-thyroglobulin levels will be measured in 3 months intervals for a period of 12 months.
Conditions
- Graves' Ophthalmopathy
Interventions
- PROCEDURE
-
Total Thyroidectomy
Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
- DRUG
-
Propylthiouracil
150-600 mg in two-three divided doses
Sponsors & Collaborators
-
Ankara University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-01-31
- Primary Completion
- 2010-06-30
- Completion
- 2010-08-31
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T)
NCT00693147 ·Status: COMPLETED ·Phase: NA
-
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
NCT01295333 ·Status: COMPLETED ·Phase: PHASE3
-
Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH
NCT04577664 ·Status: UNKNOWN ·Phase: NA
-
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
NCT04776993 ·Status: RECRUITING ·Phase: PHASE3
-
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
NCT00946296 ·Status: COMPLETED ·Phase: PHASE4
-
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
NCT00430547 ·Status: COMPLETED ·Phase: NA
-
Postoperative Hyperthyroidism
NCT01095341 ·Status: COMPLETED
-
Classic Total Thyroidectomy With or Without Drains
NCT00691990 ·Status: COMPLETED ·Phase: NA
-
Comparative Study of Different I-131 Doses in Graves' Disease
NCT02114619 ·Status: UNKNOWN ·Phase: NA
-
Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT)
NCT00692835 ·Status: COMPLETED ·Phase: NA
-
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
NCT01114503 ·Status: TERMINATED ·Phase: PHASE2
-
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
NCT07261345 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Early Levothyroxine Post Radioactive Iodine
NCT01950260 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Iodine Supplementation in Graves' Hyperthyroidism
NCT06540469 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Clinical Study Investigating the Effect of Sodium Nitroprusside Infusion on Thyroidal Function
NCT00636584 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of the Application of Head Mounted Magnifying Glasses on Postoperative PTH Changes in Thyroid Surgery: Stage II
NCT06838728 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
NCT01204359 ·Status: UNKNOWN ·Phase: PHASE3
-
Outcomes of Thyroid Auto Transplantation Following Total Thyroidectomy in Benign Thyroid Disorders Protocol
NCT05930977 ·Status: UNKNOWN
-
Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy with Central Lymph Node Compartment Dissection
NCT04339478 ·Status: COMPLETED
-
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
NCT07040306 ·Status: RECRUITING
-
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
NCT07152366 ·Status: RECRUITING ·Phase: PHASE4
-
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
NCT07129642 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Low Doses of Cholestyramine in the Treatment of Hyperthyroidism
NCT00677469 ·Status: COMPLETED ·Phase: NA
-
Thyroid Hormone Values and Anti-thyroid Peroxidase Antibody Positivity in Recurrent Pregnancy Loss
NCT05680376 ·Status: COMPLETED
-
Complications After Thyroid Surgeries: 10 Years' Experience
NCT05699304 ·Status: COMPLETED